Similar reductions of RhoA-GTP by Tazemetostat and the kinase inhibitors were observed in three other lung cancer lines (NCI-H23, NCI-H460, and SW900) that express DLC1 mRNA but lack detectable DLC1 protein (Supplementary Fig. 1B–F). This evidence concerns the gene RHOA and lung carcinoma.